All Novartis articles
-
BusinessHaleon emerges from GSK consumer healthcare spin-off
Split illustrates move towards narrower focus in pharmaceuticals
-
BusinessNovartis cutting up to 8000 jobs
Restructure splits commercial activities geographically instead of by treatment area
-
OpinionLooking beyond the next wave
We need to apply lessons from Covid-19 to tackle antimicrobial resistance and climate change
-
OpinionWill Novartis's data manipulation damage relations with regulators?
Trust between the two has been compromised
-
PodcastMethylphenidate (Ritalin)
Jamie Durrani diverts his attention to the rise of Ritalin, a drug first identified as a way of improving tennis performance
-
BusinessNovartis to cut over 2000 jobs
Move exemplifies a wave of manufacturing cuts as pharma moves to more high-value, specialised medicines
-
BusinessEurope opens gates to CAR-T
First two modified T-Cell cancer therapies approved in the EU, but prices may be prohibitive for public health systems
-
BusinessNovartis exit from antibiotics a setback for race against resistance
Experts say business models must change to halt big pharma exodus
-
BusinessTrump coaxes big promises from big pharma
Several drug industry giants are now pledging to freeze price increases in the US, but some suggest the movement is a publicity stunt or worse
-
BusinessUS senators launch probe of Novartis’ payments to Trump lawyer
Congress demands info from Novartis about its $1.2m in outflows to Michael Cohen, just as it was negotiating payments for its cancer drug
-
FeatureSolvents and sustainability
Organic solvents make up a huge part of the waste from the chemical industry. Clare Sansom looks at efforts to reduce the loss or replace them entirely
-
BusinessNovartis’ $8.7bn AveXis deal shows gene therapy appeal
Acquisition indicates the value of potentially permanent cures for inherited diseases
-
BusinessNovartis to buy AAA for radioligand cancer drugs
$3.9bn deal follows European approval of Advanced Accelerator Applications’ first-in-class radionuclide drug Lutathera
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
-
FeatureThe flow revolution
Continuous approaches are starting to find use in fine chemicals, as Angeli Mehta discovers
-
Business
Novartis on winter deal spree
Swiss company aims to re-stock drug pipeline with three new deals in skin, eye and cardiovascular health
-
BusinessNovartis consolidates research sites
Company will close research sites in China and Switzerland, and relocate another from Singapore to US
-
BusinessNovartis reshuffle puts 120 staff at risk
Commitment to gene and cell therapy treatments emphasised as unit broken up amid pharmaceutical division refocus
-
BusinessNovartis partners with Xencor for cancer antibodies
Deal deepens Novartis’s focus on immuno-oncology